Lawsuit Alleges Zantac Caused Plaintiff's Colon Cancer

Add colon and colorectal cancer to the list of diseases that allegedly have been caused by the popular heartburn medicine

Monday, April 13, 2020 - The types of cancer that are being linked to antacid drug Zantac and others have expanded to include colon cancer according to a complaint filed last month in the US District Court in the Northern District of Georgia against the drug's maker Sanofi. As with other lawsuits, plaintiff Georgia woman Bobbie Serviss, claims that using Zantac regularly and over two decades led to her colorectal cancer. The lawsuit alleges that Sanofi failed to warn patients that their drug contained N-Nitrosodimethylamine (NDMA), a chemical that is given to laboratory test animals to induce cancer and highly carcinogenic in humans. About Lawsuits.com told their readers that the plaintiff: "was diagnosed with colon cancer in May 2018. However, it would be more than a year later before she discovered that there may be a connection between her use of Zantac and cancer diagnosis." AL further described the nature of the lawsuit by quoting the attorney for Serviss as alleging: "Defendants were fully aware of the safety risks of Zantac, particularly the carcinogenic potential of Zantac as it transforms into NDMA within the chemical environment of the human body, Nonetheless, Defendants deliberately crafted their label, marketing, and promotion to mislead consumers." Heartburn medicine cancer lawyers can help people suffering from Zantac heartburn medication cancer and offer a free consultation before filing a claim.

Zantac (ranitidine), is a histamine-2 blocker that has grown in terms of sales over the years to be one of the country's most popular anti-heartburn medications. The drug works by reducing the amount of acid in the stomach. "Zantac is also used to treat gastroesophageal reflux disease (GERD) and other conditions in which acid backs up from the stomach into the esophagus, causing heartburn," according to Drugs.com. Wikipedia describes the drug as "a medication which decreases stomach acid production. It is commonly used in the treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. NDMA is "a volatile yellow oil... that has attracted wide attention as being highly hepatotoxic and a known carcinogen in lab animals."

Zantac's cancer connection was exposed in September of 2019 when innovative online startup company Valisure tested the drug for potency to ensure that their customers were receiving a proper dosage and found the carcinogen N-Nitrosodimethylamine (NDMA), originally a byproduct of rocket fuel. Valisure immediately filed a petition with the US. Food and Drug Administration (FDA) urging them to recall all drugs containing with NDMA although to this day the FDA has declined to do so. Since then, manufacturers of heartburn and antacid drugs such as Sanofi and others have voluntarily recalled the drug that was available over the counter or by prescription at major drug retailers Walgreen, Walmart, Rite Aid, and CVS.

Valisure.com issued the following NDMA warning: "Valisure's research, along with that of Stanford University and others, found that NDMA was the result of the "nherent instability" of the ranitidine molecule. This means that all manufacturers, brand or generic, and all lots of ranitidine-containing medications are affected and could generate very high levels of NDMA in the human body."

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
• Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
• Scientific Hearings Will Start This September To Interview Zantac Cancer Expert Witnesses | 5/19/2022
• A Whistleblower Scientist Working For A Chinese Company Thinks NDMA Contamination Started In China | 5/12/2022
• Valisure's String Of Stunning Success Casts Doubt On The FDAs Ability To Police The Health Care Market | 5/2/2022
• Zantac Testing Accusations Heat Up With FDA Investigation Of Online Prescription Drug Testing Lab | 4/25/2022
• Study Finds Ranitidine Degrades Into 10,000 Nanograms of NDMA When Introduced To Simulated Stomach Conditions | 4/6/2022
• Potential Zantac Expert Witnesses Are Being Questioned By Zantac Defense Attorneys | 3/31/2022
• The FDA Requires That Drug Companies Regularly Test Ranitidine And Other Drug For NDMA | 3/24/2022
• Update: Where The Zantac Cancer Multidistrict Litigation (MDL) Stands Today | 3/12/2022
• Zantac Cancer Plaintiffs Look To The First Trial In October In Alameda California | 3/11/2022
• Zantac Cancer Plaintiffs Have Until June 30 To Finalize Their Claim | 3/7/2022
• Zantac Bellwether Trials May Focus On Ranitidine Testing Methods That Could Cause NDMA To Accelerate | 3/1/2022
• Valisure LLC's Motivations And Ranitidine Testing Methods May Not Be Scrutinized Before Trial | 2/24/2022
• Zantac Lawsuits May Go To Trial In California In October Of This Year | 2/18/2022
• Sanofi's History Of Reprehensible Corporate Behavior May Bolster Zantac Cancer Lawsuits | 2/10/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.